C21.1 Insurance Policy Changes

ICD-10 C21.1 is officially defined as "Malignant neoplasm of anal canal." code C21.1 is referenced in 9 tracked payer policy changes from Independence Blue Cross, Aetna, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code C21.1 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Independence Blue Cross · Effective Jul 13, 2026Medium impact
MA08.049r, Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound)/(Abraxane® for Injectable Suspension)
Independence Blue Cross Medicare Advantage updated policy MA08.049r effective 07/13/2026 to expand Abraxane® (paclitaxel protein-bound) coverage to include cervical cancer and vaginal cancer per NCCN guidelines, while removing coverage for anal cancer. Two new ICD-10 codes were added for KSHV and immune mechanism disorders, and one unspecified breast cancer code was removed.
Independence Blue Cross · Effective Jun 1, 2026Medium impact
MA08.186a, Penpulimab-kcqx
Independence Blue Cross Medicare Advantage policy MA08.186b expands coverage for penpulimab-kcqx to include three new cancer indications (anal carcinoma, appendiceal cancers, and small bowel adenocarcinoma) effective June 1, 2026, and revises head and neck cancer criteria per FDA and NCCN guidelines. Billing teams must add 13 new ICD-10 diagnosis codes and update prior authorization and coverage criteria in billing systems.
Independence Blue Cross · Effective Jun 1, 2026Medium impact
08.02.42a, Penpulimab-kcqx
Independence Blue Cross expanded Penpulimab-kcqx coverage effective June 1, 2026 to include three new cancer indications (anal carcinoma, appendiceal cancers, small bowel adenocarcinoma) and revised head and neck cancer criteria, adding 12 new ICD-10 diagnosis codes. Billing teams must update systems to recognize these new diagnosis codes and apply the specific medical necessity criteria for coverage determinations.
Aetna · Identified Nov 5, 2026Medium impact
High-Resolution Anoscopy (CPB 0808, reviewed 2026-10-29)
Aetna's Clinical Policy Bulletin 0808 (last reviewed 2026-10-29) restates when high-resolution anoscopy (HRA) is considered medically necessary: for diagnosing suspicious anal lesions in patients with abnormal anal findings and for guiding biopsy and ablation of high-grade anal intraepithelial neoplasia. HRA for screening asymptomatic persons, estimating treatment-failure risk after chemoradiotherapy, and routine surveillance after treated anal squamous cell carcinoma is listed as experimental/investigational/unproven. The source states no effective date for a new change; the listed effective date is 11/19/2010, and the next review is 09/09/2027.
Aetna · Identified Aug 17, 2026Medium impact
High-Resolution Anoscopy (CPB 0808, reviewed 2025-11-20)
Aetna considers high-resolution anoscopy (HRA) medically necessary to diagnose a suspicious anal lesion in persons with abnormal anal physical findings, and for HRA guidance for biopsy and ablation of high-grade anal intraepithelial neoplasia. Aetna considers HRA experimental, investigational, or unproven for screening asymptomatic persons for anal dysplasia and anal cancer, for estimating the risk of treatment failure of anal canal carcinoma after chemoradiotherapy, and for surveillance after treatment for anal squamous cell carcinoma. Current evidence is insufficient to establish routine HRA surveillance after treated anal squamous cell carcinoma as universally medically necessary.
Aetna · Identified Aug 15, 2026Medium impact
Ipilimumab (Yervoy) (CPB 0815, reviewed 2026-07-16)
Aetna's Clinical Policy Bulletin 0815 covers ipilimumab (Yervoy) for commercial medical plans. It considers ipilimumab medically necessary for the cancer indications listed in the policy, many of them in combination with nivolumab, and considers continued treatment medically necessary for members requesting reauthorization when there is no evidence of unacceptable toxicity or disease progression. It considers ipilimumab experimental, investigational, or unproven for indications such as glioblastoma, pancreatic cancer, and prostate cancer, and for use with bevacizumab, vemurafenib, dabrafenib, or trametinib.
Aetna · Identified Aug 13, 2026Medium impact
Paclitaxel, Albumin-Bound (CPB 0834, reviewed 2026-05-28)
Aetna considers albumin-bound paclitaxel (Abraxane or generic albumin-bound paclitaxel) medically necessary for the cancers listed in its initial approval criteria, including Kaposi sarcoma, breast cancer, cutaneous melanoma, endometrial carcinoma, ovarian, fallopian tube and primary peritoneal cancer, biliary tract cancers, non-small cell lung cancer, pancreatic adenocarcinoma, small bowel adenocarcinoma, uveal melanoma, ampullary adenocarcinoma, cervical cancer, bladder cancer and vaginal cancer, when each cancer's stated criteria are met. All other indications are considered experimental, investigational, or unproven, including small cell lung cancer, prostate cancer, soft-tissue sarcoma and gastric cancer. Continuation of therapy is medically necessary for an approved indication when there is no evidence of unacceptable toxicity or disease progression on the current regimen.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Intensity-Modulated Radiotherapy (IMRT): Abdomen, Pelvis and Chest
Intensity-modulated radiotherapy may be considered medically necessary as an approach to delivering radiotherapy for individuals with cancer of the anus and anal canal. When dosimetric planning with standard 3D conformal radiotherapy predicts that the radiation dose to an adjacent organ would result in unacceptable normal tissue toxicity, IMRT may be considered medically necessary for cancer of the abdomen and pelvis, including stomach, hepatobiliary tract, pancreas, esophageal cancer, rectal locations, and gynecologic tumors (cervical, endometrial, and vulvar cancers). IMRT is investigational for all other uses in the abdomen and pelvis. For IMRT to provide outcomes superior to 3D-CRT, there must be a clinically meaningful decrease in radiation exposure to normal structures compared with 3D-CRT.
Independence Blue Cross · Effective Oct 1, 2026Low impact
08.02.42b, Penpulimab-kcqx
Independence Blue Cross updated policy 08.02.42b for Penpulimab-kcqx effective 10/01/2026, adding ICD-10 code C78.32 (secondary malignant neoplasm of pharynx) to the covered diagnosis codes. This is a coding update that expands the policy's diagnostic scope for this immunotherapy drug used in various cancer treatments.

Watch C21.1

Get one email when a payer policy names C21.1, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code C21.1?

There are 9 tracked policy changes affecting code C21.1, including updates from Independence Blue Cross, Aetna, Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code C21.1?

Payers that have issued tracked updates for code C21.1 include: Independence Blue Cross, Aetna, Blue Cross & Blue Shield of Mississippi.

How do I get notified when code C21.1 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code C21.1. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code C21.1?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

MA08.049r, Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound)/(Abraxane® for Injectable Suspension)

MA08.186a, Penpulimab-kcqx

08.02.42a, Penpulimab-kcqx

High-Resolution Anoscopy (CPB 0808, reviewed 2026-10-29)

High-Resolution Anoscopy (CPB 0808, reviewed 2025-11-20)

Ipilimumab (Yervoy) (CPB 0815, reviewed 2026-07-16)

Paclitaxel, Albumin-Bound (CPB 0834, reviewed 2026-05-28)

Intensity-Modulated Radiotherapy (IMRT): Abdomen, Pelvis and Chest

08.02.42b, Penpulimab-kcqx

What insurance policy changes affect code C21.1?

Which payers have updated policy for code C21.1?

How do I get notified when code C21.1 policy changes?

Why do payers change policies for code C21.1?